Tudor Eliade C.
- Country
- Romania
- Department
- AEM in colab.with Inst.of Onc.Pr.Dr.I.Chiricuta,Med.Onc.I-Hosp.Build.4th fl,Wrds 329,330,331
Research Overview
- Pharmacokinetic Comparison of FYB206 and Pembrolizumab in Adjuvant Treatment of Stage IIB, IIC, or III Melanoma Post-Resection
- Pharmacokinetic and Safety Evaluation of Oral Decitabine and Cedazuridine in Patients with Solid Tumors, Myelodysplastic Syndrome, or Acute Myeloid Leukemia with Hepatic Impairment
- Phase 3 Randomized Study of Nivolumab and Ipilimumab with Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 490 of 749 partner sites.
Specializations
Thoracic Oncology
Clinical research activity is strongly centered on non-small cell lung cancer and small cell lung cancer, with interest across locally advanced, metastatic, resectable, and recurrent disease settings. The portfolio also includes molecularly defined lung cancer populations such as EGFR-mutated, ALK-positive, ROS1-rearranged, RET fusion-positive, and KRAS G12C-mutant disease.
- Non-small cell lung cancer
- Small cell lung cancer
- Metastatic and resectable thoracic malignancies
- Biomarker-directed lung cancer
Therapeutic activity spans immunotherapy, targeted therapy, chemoradiation, and perioperative treatment strategies in lung cancer.
Breast and Gynecologic Oncology
The investigator is involved in studies of breast cancer across early, locally recurrent, and metastatic settings, including HER2-positive, hormone receptor-positive, and triple-negative breast cancer. Research also extends to ovarian cancer, endometrial cancer, fallopian tube cancer, and primary peritoneal cancer.
- HER2-positive and HR-positive breast cancer
- Triple-negative breast cancer
- Ovarian and endometrial malignancies
- Gynecologic and metastatic solid tumors
Therapeutic interests include endocrine therapy, HER2-directed therapy, antibody-drug conjugates, and immunotherapy in women’s cancers.
Hematologic Malignancies
Research involvement covers a broad spectrum of blood cancers, including acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, chronic lymphocytic leukemia, and multiple forms of non-Hodgkin lymphoma such as diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
- Acute and chronic leukemias
- Myeloproliferative neoplasms
- B-cell lymphomas
- Plasma cell disorders
Therapeutic focus includes JAK inhibition, B-cell–directed therapy, cellular therapy, and treatment approaches for relapsed or refractory hematologic disease.
Genitourinary and Gastrointestinal Cancers
Clinical trial activity includes prostate cancer, urothelial cancer, renal cell carcinoma, bladder cancer, hepatocellular carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, esophageal cancer, and colorectal cancer.
- Prostate and bladder cancers
- Renal and urothelial malignancies
- Hepatobiliary and upper gastrointestinal cancers
- Colorectal and pancreatic tumors
Therapeutic interests include androgen receptor–targeted treatment, checkpoint inhibition, anti-angiogenic therapy, and combination strategies for advanced solid tumors.
Melanoma and Other Immune-Mediated Conditions
The investigator also participates in studies of melanoma, head and neck squamous cell carcinoma, and cutaneous squamous cell carcinoma, alongside non-oncologic immune-mediated disorders such as systemic lupus erythematosus, systemic sclerosis, rheumatoid arthritis, and immune thrombocytopenia.
- Melanoma
- Head and neck squamous cell carcinoma
- Cutaneous squamous cell carcinoma
- Autoimmune and inflammatory diseases
Therapeutic emphasis includes immuno-oncology and selected immune-modulating therapies across cancer and autoimmune disease settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.